DDInter94 DDInter1376
Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta. Anakinra is indicated for the management of rheumatoid arthritis (RA) in patients 18 years of age or older who have failed one or more disease-modifying antirheumatic drugs (DMARDs), as well as the treatment of neonatal-onset multisystem inflammatory disease (NOMID) and deficiency of interleukin-1 receptor antagonist (DIRA). Since IL-1 has an important role in inflammation and immunological responses, anakinra is also used for the off-label treatment of inflammatory diseases. Anakinra is produced using the _
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Anakinra {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc sulfate
Anakinra {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mycophenolate mofetil
Anakinra {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Denileukin diftitox
Anakinra {u} may lead to a major life threatening interaction when taken with {v} Upadacitinib
Anakinra {u} may lead to a major life threatening interaction when taken with {v} Etanercept
Anakinra may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolate mofetil
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Denileukin diftitox
Anakinra may lead to a major life threatening interaction when taken with Upadacitinib
Anakinra may lead to a major life threatening interaction when taken with Etanercept